BBA
AVNR

BLB&B Advisors’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

BLB&B Advisors’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-12,500
Closed -$46K – 300
2014
Q1 		$46K Hold
12,500
– – 0.01% 273
2013
Q4 		$42K Hold
12,500
– – 0.01% 249
2013
Q3 		$53K Buy
+12,500
New +$59.2K 0.01% 240

Other funds holding AVNR

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

BLB&B Advisors's AVNR Position: Q2 2014 in Review

BLB&B Advisors sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q2 2014, closing a stake of 12,500 shares — an estimated $46K sold.

BLB&B Advisors first reported a position in AVNR in Q3 2013 and held it in 3 quarters. The position peaked at $53K in Q3 2013. 115 funds tracked by Wall St. Rank hold AVNR as of Q2 2014.

  • BLB&B Advisors reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q2 2014 after selling out during the quarter.
  • BLB&B Advisors sold 12,500 AVANIR PHARMACEUTICALS, INC CL A shares in Q2 2014, an estimated $46K.
  • BLB&B Advisors first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q3 2013 and held it in 3 quarters.
  • BLB&B Advisors's AVANIR PHARMACEUTICALS, INC CL A position peaked at $53K in Q3 2013.
  • 115 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q2 2014.

Based on BLB&B Advisors's 13F filing for Q2 2014, filed 17 Jul 2014.